Altimmune Company Description

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.

The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.

The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015.

Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Altimmune, Inc.

Country	United States
Founded	1997
Industry	Biological Products, Except Diagnostic Substances
Employees	59
CEO	Vipin Garg

Contact Details

Address: 910 Clopper Road Gaithersburg, Delaware 20878 United States
Phone	240 654 1450
Website	altimmune.com

Stock Details

Ticker Symbol	0A4C
Exchange	London Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Vipin Garg	Chief Executive Officer
Gregory Weaver	Chief Financial Officer